Abstract
The three defining blocks of a β-blocker drug are the pharmacodynamic properties of the active ingredient (PD), the pharmacokinetic features (PK), and the dosage form (DF). The drug of choice β-blocker with pronounced clinical efficacy and a favorable safety profile is distinguished by: 1) high selectivity for target β-adrenergic receptors (mainly PD, PK); 2) high bioavailability and permeability of histohematic barriers (PK, LF); 3) maintaining plasma concentrations in the therapeutic range (PK, LF); 4) frequency of administration once a day (PD, duration of complex formation with receptors; PK, LF); 5) minimization of pharmacokinetic drug interactions (PK); 6) no relationship with food intake (PK). The clinical and pharmacological advantages of metoprolol succinate (Betaloc® ZOK) include long-term action, improved tolerability, control of blood pressure during the day, less pronounced side effects and drug interactions, ease of administration.
Keywords: metoprolol succinate, prolonged form, bisoprolol.
Keywords: metoprolol succinate, prolonged form, bisoprolol.
For citation:Dukhanin A.S. Three pharmacological blocks of a drug based on a β-adrenergic blocker: a strategy for its creation and effective clinical use. Clinical review for general practice. 2024; 5 (11): 37–43 (In Russ.). DOI: 10.47407/kr2024.5.11.00432
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
